F.S. Hodi

TL;DR: Among patients with advanced melanoma, sustained long-term overall survival at 5 years was observed in a greater percentage of patients who received nivolumab plus ipilimumab or nivoliumab alone than in those who received ipil optimumab alone, with no apparent loss of quality of life in the patients whoreceived regimens containing nivolinumab.

TL;DR: The results presented in this report reflect the 4-year update of the ongoing study with a database lock date of May 10, 2018.

TL;DR: Clinical benefit was associated with loss-of-function mutations in the PBRM1 gene, which encodes a subunit of the PBAF switch-sucrose nonfermentable (SWI/SNF) chromatin remodeling complex, and may alter global tumor-cell expression profiles to influence responsiveness to immune checkpoint therapy.

TL;DR: This 5-year analysis of KEYNOTE-001 represents the longest follow-up for pembrolizumab to date and confirms the durable antitumor activity and tolerability of pembrolezumab in advanced melanoma.

TL;DR: Positive PD-L1 expression in TIMCs was significantly associated with longer survival in those patients who developed metastases and was not predictive of OS, but widely expressed in tumor cell membrane and TIMCs in UC.